TNFSF10 and neoplasm: Nevertheless, TRAIL dosage (100 μg) in this therapy was too low to synergize with IVM and/or CQ to reduce tumor growth and activate death receptor signaling (in terms of procaspase-8/cleaved caspase-8 ratio) as potent as those in vitro, especially when tumors were big.